Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.
By Stefan Baral, Wesley Pegden, Vinay Prasad
The rapid development of highly effective COVID-19 vaccines is a triumph of science and, with equitable implementation strategies, represents humanity’s path out of the COVID-19 pandemic. To expedite deployment in the U.S., three COVID-19 vaccines were provided Emergency Use Authorization (EUA) while concurrently undertaking the traditional review process.
Pfizer has requested the FDA amend the existing EUA for its vaccine to allow eligibility for children aged 12 to 15, and further clinical trials of COVID-19 vaccines, including for younger children, are underway. Unlike for adults, however, the likelihood of severe outcomes or death associated with COVID-19 infection is very low for children, undermining the appropriateness of an EUA for child COVID-19 vaccines.
Emergency Use Authorization in the U.S. requires that an intervention address a serious or life-threatening condition, and for known and potential benefits of the intervention to be balanced against the known and potential harms. The EUA for COVID-19 vaccines were implemented at the height of the second wave in the U.S., enabling 100 million American adults, who would otherwise be at significant risk of severe outcomes or death from COVID-19 infection, to be vaccinated on an accelerated time frame.
Significant adverse events to vaccines are sometimes detected during wider distribution; for example, such events were investigated for the Johnson and Johnson COVID-19 vaccine. But Phase 3 trials of COVID-19 vaccines in adults demonstrated reductions in both infections and severe disease, and even if one reasoned conservatively from data on infections alone, these trials showed a large benefit for adult populations that convincingly offset the potential for harms from any side effects rare enough to be missed in Phase 3 trials. Collectively, COVID-19 vaccination in adults met EUA criteria given the positive balance of risks and benefits at the individual level.
Trials for COVID-19 vaccines are also underway for children as young as 6 months. These trials are not powered to measure decreases in severe COVID-19 infections, due to their rarity. Instead, these trials are examining safety, the immune response, and, as a secondary outcome, the impact on the incidence of COVID-19 infections. As for adults, these trials are not designed to assess rare or delayed adverse events.
Unlike for adults, the rarity of severe COVID-19 outcomes for children means that trials cannot demonstrate that the balance of the benefits of vaccination against the potential adverse effects are favorable to the children themselves. In short, given the rarity of severe clinical courses and limited clarity of risks, the criteria for Emergency Use Authorization do not appear to be met for children.
Emergency Use Authorizations for child vaccinations can make sense for children for whom the benefits are greatest, and thus for whom it is clearest that the benefits outweigh any unknown harms. In the near-term, EUA’s should be considered for children at genuinely high risk of serious complications from infection. It is also worth considering whether emergency use could be authorized for children whom especially concerned caregivers are sheltering from school or social interactions.
The small risk posed to children by COVID-19 does not merit restrictions on any normal child activities in a context where adults are protected by vaccines, but individual children who find their lives curtailed in this way may obtain significant benefits from vaccination.
One might hope to achieve population-level benefits with broader child vaccination, even while the relative benefits and risks for children themselves remain unclear. But this is inconsistent with the conditions for Emergency Use Authorization. Fortunately, COVID-19 vaccines have shown very high effectiveness across the adult population, and future trajectories of hospitalizations and deaths will largely be determined by vaccination rates in adults.
In 1976, the vaccination campaign in anticipation of a deadly Swine flu (H1N1) epidemic inoculated 45 million Americans before being derailed by very rare cases of Guillain-Barré syndrome. That year saw less flu-related morbidity and mortality than expected, and these few hundred adverse events cast a long shadow on American vaccination programs, affecting attitudes towards influenza vaccines for years to come.
This highlights an important tradeoff when accelerating approval of pharmaceutical interventions in the context of an emergency. Specifically, that risk of rare adverse events remains. And if the benefit achieved by an intervention is insufficient, serious, yet rare, adverse effects can prove to be the lasting legacy of a regulatory decision.
For adults, the benefits of COVID-19 vaccination are enormous, while for children, they are relatively minor. Rare side effects from adult COVID-19 vaccination are unlikely to lead to future vaccine hesitancy whose public health impact could be comparable to the benefits of the adult COVID-19 vaccination program itself.
But accelerated mass child vaccination under EUA — perhaps even spurred by school mandates and “vaccine passports” — presents a different balance of risks and benefits. Rare adverse events really could prove to be the most durable public health legacy of an EUA for child COVID-19 vaccines.
Even in the likely scenario that no significant adverse events materialize, we may pay a price for the pursuit of EUA’s for COVID-19 vaccines in children. Controversy surrounding mass child vaccination under EUA’s could feed vaccine hesitancy in the U.S. at a time when public attitudes towards vaccination are critical. A wide rollout of child COVID-19 vaccines should follow the standard regulatory process as for most children, unlike adults, COVID-19 vaccination is not addressing an emergency.
Originally published by Medium.